Grid radiation therapy with megavoltage x-ray beam has been proven to be an effective technique for management of large, bulky malignant tumors. The clinical advantage of GRID therapy, combined with conventional radiation therapy, has been demonstrated using a prototype GRID block ͓Mohiuddin, Curtis, Grizos, and Komarnicky, Cancer 66, 114-118 ͑1990͔͒. Recently, a new GRID block design with improved dosimetric properties has become commercially available from Radiation Product Design, Inc. ͑Albertive, MN͒. This GRID collimator consists of an array of focused apertures in a cerrobend block arranged in a hexagonal pattern having a circular cross-section with a diameter and center-to-center spacing of 14.3 and 21.1 mm, respectively, in the plane of isocenter. In this project, dosimetric characteristics of the newly redesigned GRID block have been investigated for a Varian 21EX linear accelerator ͑Varian Associates, Palo Alto, CA͒. These determinations were performed using radiographic films, thermoluminescent dosimeters in Solid Water™ phantom materials, and an ionization chamber in water. The output factor, percentage depth dose, beam profiles, and isodose distributions of the GRID radiation as a function of field size and beam energy have been measured using both 6 and 18 MV x-ray beams. In addition, the therapeutic advantage obtained from this treatment modality with the new GRID block design for a high, single fraction of dose has been calculated using the linear quadratic model with ␣ / ␤ ratios for typical tumor and normal cells. These biological characteristics of the new GRID block design will also be presented.
I. INTRODUCTION
Megavoltage GRID radiation therapy is a new paradigm in the management of bulky ͑Ͼ8 cm͒ malignant tumors. [1] [2] [3] [4] The Department of Radiation Medicine at the University of Kentucky has utilized a modified spatially fractionated technique with megavoltage x-ray beam for treatment of advanced tumors. 3, 4 Dosimetric characteristics of these GRID radiation fields for both photon and electron beams have been studied by several investigators. [5] [6] [7] It is interesting to know that the published clinical results [1] [2] [3] [4] were obtained with a prototype GRID block that was constructed by placing several segments of copper tubing between two plastic trays and filling the space between the tubes with cerrobend material. Therefore, the differences in attenuation between the copper tubing and cerrobend material, as well as the nondivergent match problem of the copper tubing to the divergent beam, brought about a challenge to the design of the prototype GRID block. Despite the problems mentioned above in the prototype GRID block design, Mohiuddin et al. 3 have shown that the overall response rate of patients increased from 62% to 91% when they were treated with a single-field GRID irradiation of ജ15 Gy plus conventional external beam therapy.
Recently, a new GRID block has been designed and fabricated by Radiation Product Design, Inc. ͑5218 Barthel Industrial Dr., Albertive, MN͒. This block was constructed by casting the divergent holes in a cerrobend block, using a stereotactic method which is able to provide the optimal conditions of: ͑1͒ accurate beam divergence and ͑2͒ less transmission through the blocked area. This block design allows for a greater volume of tissue to receive the therapeutic dose of greater than 85%. The hole size and center-to-center spacing can be customized, and also the divergence of the holes can be designed to match one of the commercially available linear accelerators. Characterization of the dosimetric and biological properties of the new GRID block design is necessary for clinical implementation.
While the evaluation of dosimetric properties of GRID irradiation is relatively straightforward, the biological analysis is much more difficult. The radiobiology of GRID irradiation is not well understood and is currently being studied by several investigators. 8, 9 Proposed mechanisms of action include the production of various cytokines in the irradiated tissues. 9 For a nonuniform radiation field, Niemierko 10 introduced a radiobiological model, based on the linear quadratic model, to describe the biological effectiveness of the inho-mogeneous dose distribution such as three-dimensional ͑3D͒ conformal therapy. Zwicker et al. 11 have extended this model to evaluate radiobiological properties of GRID irradiation. They have concluded that for a wide range of tumor tissue sensitivities, a single-dose partial-volume GRID radiation field may have a significant therapeutic advantage over open field radiotherapy in sparing normal tissues.
The goal of this project is to investigate the physical and biological characteristics of the megavoltage photon radiation through this newly designed GRID block for a Varian 21EX linear accelerator ͑Varian Associates, Palo Alto, CA͒. Dosimetric characteristics ͓i.e., beam profiles, isodose distributions, output factor, and percent depth dose ͑%DD͒ of radiation field͔ for this block design were experimentally determined. Measurements were performed for 6 and 18 MV x-ray beams using radiographic film and thermoluminescent dosimeters ͑TLDs͒ in Solid Water™ phantom material ͑Ra-diation Measurements Inc., RMI, Middleton, WI͒ and an ionization chamber in water. The biological analysis of the new GRID block utilizes the above mentioned model by Zwicker et al.
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II. MATERIALS AND METHODS
A. Grid design
The GRID block used in the current experiment was manufactured by Radiation Products Design, Inc. This block was constructed by casting a hexagonal array of divergent holes 14.3 mm in diameter with 21.1 mm center-to-center spacing projected in the plane of isocenter. The apertures were cast in a 7.5-cm-thick cerrobend block. The divergence of the holes was designed for a Varian 21EX linear accelerator having a source-to-tray distance of 65.4 cm. Similar to the prototype GRID block, the new GRID aperture design provides approximately 41.7% open area at isocenter. Various field sizes up to a maximum of 25ϫ 25 cm can be achieved with this block design. Figure 1͑a͒ shows the top view of the GRID block. Figure 1͑b͒ illustrates the GRID block mounted in the block tray holder of the Varian 21EX linear accelerator.
B. Film dosimetry
Film dosimetry was utilized to obtain beam profiles for the GRID collimated fields using 6 and 18 MV photon beams from a Varian Clinac 21EX linear accelerator. The measurements were performed in Solid Water™ phantom materials using Kodak X-Omat V radiographic film ͑East-man Kodak Company, Rochester, NY͒. The beam profiles were measured along the two orthogonal directions ͑in plane and cross plane͒ in a plane perpendicular to the central beam axis. These measurements were performed at depths of dmax, 5 cm, and 10 cm in 23-cm-thick Solid Water™ phantom material for 6 and 18 MV x-ray beams ͑Fig. 2͒. The irradiated films were read with a Lumiscan-50 laser scanner ͑Lumisys, Sunnyvale, CA͒ and processed with MEPHYSTO software ͑Version 6.30, PTW-New York Co., Hicksville, New York͒, Microsoft Excel, and Origin® Version 6.1 ͑Orig-inLAB Corp, One Roundhouse Plaza, Northampton, MA͒. Batch-and energy-specific calibration curves were used to obtain doses for the measured transmittance. Calibrations were obtained for doses of 1, 5, 10, 20, 30, 50, 60, and 70 cGy using a 10ϫ 10 cm open field at 100 cm SSD at depth of dmax in Solid Water™ phantom material.
C. TLD technique and phantom design
TLD measurements were performed at depths of dmax, 5 cm, and 10 cm for both 6 and 18 MV x-ray beams using LiF TLD chips ͑TLD-100, Thermo Electron Corp., Oakwood Village, OH͒ in Solid Water™ phantom material. This phantom material was accurately machined to accommodate the 1 ϫ 1 ϫ 1 mm 3 TLD chips at the center of the GRID holes and blocked areas ͑Fig. 3͒. The irradiated TLD response was obtained using a Harshaw Model 3500 TLD reader ͑Thermo Electron Corp., Oakwood Village, OH͒. The responses of at least 10 TLD chips, from the same batch of TLDs, were calibrated using open radiation field ͑i.e., 10ϫ 10 cm 2 ͒ with 6 MV x-ray beams. The corresponding responses from the TLDs irradiated in the GRID field were then converted to dose following procedures described by Meigooni et al. 12 The mean values of up to seven chips were used to evaluate each measurement point.
Application of TLD chips for radiation dosimetry in both external beam and brachytherapy fields have been demonstrated by various investigators. [12] [13] [14] [15] [16] Equation ͑1͒ was used to calculate the absorbed dose rate from the TLD responses for each point irradiated in the phantom:
where Ḋ ͑d͒ is the absorbed dose per monitor unit ͑MU͒ at depth of d, R is the TLD response corrected for background and the physical differences between the TLD chips using predetermined chip factors, MU is the monitor unit used for the exposure of TLDs, is the calibration factor for the TLD response ͑nC / cGy͒ measured with a 6-or 18-MV x-ray beam from a linear accelerator, and F lin is the nonlinearity correction of the TLD response for the given dose. In these measurements, the absorbed dose exposure level was selected to be in the range of 10-100 cGy for which F lin was assumed to be unity.
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D. Ion chamber measurements
Percent depth dose and beam profiles were measured using a Scanditronix Wellhofer 3D radiation scanning system ͑Scanditronix Wellhofer North America, Bartlett, TN͒ with a Wellhofer Model CC01 chamber. This microchamber has a sensitive volume of 0.01 cm 3 ͑1 mm radius and 3.6 mm active length͒. The chamber was scanned in the direction of the chamber diameter, which provides a sufficiently small spatial resolution, relative to the GRID hole diameter ͑14 mm͒, for dosimetry of GRID radiation field. These measurements were performed as a function of depth, field size, and beam energy. This system consisted of a standard 48ϫ 48 ϫ 48 cm 3 water tank, Wellhofer Model CU 500E dual channel control unit, and WP 700 software. For output factor measurements, the CC01 ionization chamber charge readings were obtained with an Inovision Model 35040 electrometer. Output factors were then obtained by calculating the ratio of the average charge readings for a 10ϫ 10 cm field without to with GRID block at dmax depth and 100 cm SSD.
E. Therapeutic advantage of GRID therapy
The methodology of Zwicker et al. 11 has been used to evaluate the potential therapeutic advantage of the newly designed GRID field. The overall survival fraction ͑SF͒ is determined from an area weighted average of local SF and is calculated for both normal and tumor cells. where each normal-tissue SF is calculated for the same tumor SF. The ␣ / ␤ ratios used for these calculations, 10 Gy for tumor cells and 2.5 Gy for normal cells, represent typical values for these tissue types.
III. RESULTS AND DISCUSSION
A. Dosimetric characteristics
To validate the use of different dosimeters in this investigation, the results obtained using TLD, ionization chamber, and film dosimetry were compared in graphical and tabulated formats. Tables I͑A͒ and I͑B͒show excellent agreement ͑±5 % ͒ among the three techniques in measuring the output factors for both 6 and 18 MV x-ray beams, respectively. at dmax and 100 cm SSD as a function of field size and energy in Table III . These results indicated a good agreement between open field S c,p and GRID output factors for both 6 and 18 MV photon beams. The cross-plane beam profiles for the newly redesigned GRID block were compared with those of the prototype grid.
These comparisons are shown in Figs. 5͑a͒ and 5͑b͒. These figures show good symmetry and well-patterned dose profiles for both grid designs. However, relative to the prototype grid, the new GRID block shows approximately a 50% dose reduction to the blocked regions of the field for both 6 and 18 MV photons. This reduction can be attributed to the differences of beam divergence and attenuation for the two block designs.
Figures 6͑a͒ and 6͑b͒ show the comparison of measured beam profiles using the film dosimetry technique for an open 10ϫ 10 cm 2 field versus GRID field for both 6 and 18 MV photons, respectively. The dose profiles in these figures were normalized to the central axis dose value of the open field. These figures indicate an output factor of 100% for an open field and 90% for a 6-MV GRID field. However, the output factors for 18 MV open and GRID fields were found to be 100% and 78%, respectively. These output factors are utilized for treatment planning of patients treated with GRID. Figures 7͑a͒ and 7͑b͒ represent the dose distribution and isodose curves of a GRID radiation field for 6 MV photons, respectively. These figures were obtained using the film dosimetry technique at dmax depth for a 10ϫ 10 cm field. Figure 7͑b͒ shows that the minimum contiguous isodose lines between the GRID holes were found to be approximately 12%-16%, which is consistent with TLD and ionization chamber measured data shown in Table I͑A͒ . Figure 8 shows a comparison of cross-plane beam profiles for 6 and 18 MV photons at dmax depth for a 10ϫ 10 cm field size measured with ionization chamber. This figure indicates similar dose profiles for the two photon energies.
Comparisons of GRID field profiles as a function of depth measured with the film dosimetry technique for 6 and 18 MV photons are shown in Figs. 9 and 10, respectively. Dose profiles at different depths are normalized to the CAX dose at the dmax depth for both beam energies. These figures indicate that the dose to the open region ͑i.e., hole͒ of the GRID field decreases with increasing depth, but the dose to the blocked area remains nearly constant. Therefore, the ratio of the peak-to-valley dose decreases with increasing depth. Figures 11͑a͒ and 11͑b͒ show the %DD of 6 and 18 MV GRID fields, respectively, along the depth axis of the central aperture. These data were measured with an ionization chamber in water, film dosimetry, and TLD in Solid Water™ using a 10ϫ 10 cm field size and 100 cm SSD. These results indicate an excellent agreement between the data measured with the three different techniques for both 6 and 18 MV x rays. Figure 12 demonstrates the impact of the field size on the %DD of 6 and 18 MV beams. As shown in this figure, no significant differences ͑within ±2.5% at a depth of 30 cm͒ were observed for the 18-MV beam. However, these differences increase to approximately ±10% for the 6-MV beam at a depth of 30 cm.
B. Cell survival estimation under GRID field irradiation
The surviving fractions of tumor and normal cells are expressed by a linear quadratic model for a single uniform dose irradiation in the linear-quadratic model of cell survival. Typical values for the ratio ␣ / ␤ are 10 Gy for tumor cells and 2.5 Gy for normal tissues. 17, 18 If a cell survival of 0.5 for a dose of 2 Gy is assumed, the resulting values of ␣ and ␤ will be 0.289 and 0.0289 for tumor cells and 0.193 and 0.077 for normal tissues. The therapeutic advantage of GRID irradiation was modeled in terms of the normal tissue cell survival ratio of a GRID versus an open field for the same tumor cell kill.
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Assuming identical dose distribution under each grid hole ͑Figs. 9 and 10͒ at a given depth, the dose profile under the central axis grid hole ͓Fig. 13͑a͔͒ was utilized to calculate the surviving fraction of the cells as a function of absorbed dose following Zwicker et al.'s model. 11 Figure 13͑b͒ shows the integral dose area histogram and Fig. 13͑c͒ shows the differential dose area histogram used in these calculations. The cell surviving fraction in tissue irradiated by such a dose distribution is determined and the results were utilized for evaluation of the therapeutic advantage of the GRID with Eq. ͑2͒. Figure 14 The standard linear quadratic model was employed to evaluate this GRID by studying cell survival and therapeutic advantage up to 30 Gy. On the basis of cell survival with a cell survival of 0.5 for a dose of 2 Gy assumed, large singledose fraction treatment using GRID is expected to have a remarkably therapeutic advantage over open field treatment to achieve the same level of tumor cell killing. A greater therapeutic advantage of 2.20 is, in particular, predicted with GRID therapy at a 15-Gy grid irradiation versus an open field and the therapeutic gain is found to increase with dose. Dosimetric characteristics of a GRID, and corresponding therapeutic advantages of GRID therapy, appear to increase credit in this modality for single high-dose GRID radiotherapy.
